Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2006

View Archived Issues

PD-0325901 inhibits hepatocellular carcinoma growth in vivo

GW-427353 inhibits cholinergic contraction in human colon

ZK-156979 has therapeutic effect in experimental colitis

Spectrum presents Q1 highlights

Ono updates latest developments in pipeline

Milestones in Metabolex's diabetes and obesity collaboration with Astellas

Phase IIa trial studies Phosphagenics' transdermal morphine

Orally available calpain inhibitor provides in vivo neuroprotection against retinal ischemia

BioInvent considers protocol amendment for phase I/II study of BI-201 for HIV

Canadian notice of deficiency for GlucaGen

Shire disappointed at NICE's recommendation on patients with mild Alzheimer's

PEP-005 Topical studied for cutaneous squamous cell carcinoma in situ

Herceptin plus Arimidex prolongs PFS in advanced HER2 breast cancer

Sphingosine 1-phosphate S1P1 receptor agonists emerge from Merck R&D

Bristol-Myers Squibb presents antitumor activity of new VEGFR-2 inhibitor

Pfizer present new oral PDE5 inhibitor as a candidate for male erectile dysfunction

Recent patents describe new anticoagulants

Novel alpha 1a/1d adrenoreceptor antagonists claimed for BPH treatment

Agents with potential for the treatment of metabolic disorders described in recent patents

New report from Prous Science reviews treatment options for patients with muscular dystrophy

Oracea approved for rosacea

ISTA begins pivotal studies for once-daily Xibrom

Phase II study of LE-SN-38 in metastatic colorectal cancer begins enrollment

Ortec to file HDE for cryopreserved OrCel in epidermolysis bullosa

European approval for Zostavax

Astellas returns Japanese strontium ranelate rights to Servier

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...